Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo‐controlled,double‐blind, multicentre study
The DOI matches its Crossref record.
Abstract
Summary: Aims The aim of the study was to evaluate the efficacy and safety of acarbose in patients with Type 1 diabetes mellitus (DM). Methods A multicentre double‐blind, randomized, placebo‐controlled study was performed. After a 6‐week run‐in, 121 patients were randomized to acarbose or placebo and to high‐ or low‐fibre diet for 24 weeks. Acarbose dose was 50 mg t.d.s. for the first 2 weeks and 100 mg t.d.s. for the subsequent weeks. Results At the end of 24 weeks of treatment the intention to treat analysis showed that acarbose compared with placebo decreased 2 h postprandial plasma glucose levels (12.23 ± 0.83 vs. 14.93 ± 0.87 mmol/l;F = 6.1, P < 0.02) (least square means ± sem). No significant effect of acarbose was recorded on HbA 1c or on the number of hypoglycaemic episodes. The effect of acarbose on blood glucose control was not influenced by the amount of carbohydrate and/or fibre intake. The incidence of adverse events were 75% and 39% in acarbose and placebo groups, respectively; they were mild and confined to the gastrointestinal tract. Conclusions The use of acarbose in combination with insulin reduces postprandial plasma glucose levels in Type 1 diabetic patients who are not satisfactorily controlled with insulin alone but without significant effect on HbA 1c. Diabet. Med. 16, 228–232 (1999)
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Differentiation of diabetes by pathophysiology, natural history, and prognosis
Skyler, J. S., Bakris, G. L., Bonifacio, E., Darsow, T., Eckel, R. H., Groop, L., Groop, P.-H., Handelsman, Y., Insel, R. A., Mathieu, C., et al. (2017) · Diabetes · doi:10.2337/db16-0806 · Cited by 823
Joshi, S. R., Standl, E., Tong, N., Shah, P., Kalra, S., & Rathod, R. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1070827 · Cited by 303
Pancreatogenic Diabetes: Special Considerations for Management
Cui, Y., & Andersen, D. K. (2011) · Pancreatology · doi:10.1159/000329188 · Cited by 256
The hypoglycaemic effect of pumpkins as anti-diabetic and functional medicines
Adams, G. G., Imran, S., Wang, S., Mohammad, A., Kok, S., Gray, D. A., Channell, G. A., Morris, G. A., & Harding, S. E. (2011) · Food Research International · doi:10.1016/j.foodres.2011.03.016 · Cited by 175
Management of severe insulin resistance in patients with type 1 diabetes
Schechter, R., & Reutrakul, S. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0641-2 · Cited by 15
Metadata
- Authors
- Riccardi, G., Giacco, R., Parillo, M., Turco, S., Rivellese, A. A., Ventura, M. R., Contadini, S., Marra, G., Monteduro, M., Santeusanio, F., Brunetti, P., Librenti, M. C., Pontiroli, A. E., Vedani, P., Pozza, G., Bergamini, L., & Bianchi, C.
- Venue
- Diabetic Medicine
- Publisher
- Wiley
- Published
- 1999-03
- Volume
- 16
- Issue
- 3
- Pages
- 228-232
- ISSN
- 0742-3071 (ISSN-L)
- 1464-5491
- OpenAlex
- W2071716514
- Cited by
- 50
- References
- 0
- FWCI
- 0.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo‐controlled,double‐blind, multicentre study. https://app.cochat.ai/papers/10.1046/j.1464-5491.1999.00047.x
- The paper
- Riccardi, G., Giacco, R., Parillo, M., Turco, S., Rivellese, A. A., Ventura, M. R., Contadini, S., Marra, G., Monteduro, M., Santeusanio, F., Brunetti, P., Librenti, M. C., Pontiroli, A. E., Vedani, P., Pozza, G., Bergamini, L., & Bianchi, C. (1999). Efficacy and safety of acarbose in the treatment of Type 1 diabetes mellitus: a placebo‐controlled,double‐blind, multicentre study. Diabetic Medicine. https://doi.org/10.1046/j.1464-5491.1999.00047.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.